Loading...
XNAS
VTGN
Market cap121mUSD
Oct 07, Last price  
3.96USD
1D
1.80%
1Q
59.04%
Jan 2017
-96.46%
IPO
-96.79%
Name

VistaGen Therapeutics Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
249.99
EPS
—
Div Yield, %
—
Shrs. gr., 5y
83.85%
Rev. gr., 5y
%
Revenues
486k
-54.32%
00001,342,200200,4000001,250,0000001,089,5001,108,900-227,0001,064,000486,000
Net income
-51m
L+75.12%
-4,754-16,416-21,998-8,976-12,209,500-12,886,700-2,967,700-13,885,800-47,220,500-10,255,500-14,345,900-24,589,600-20,774,000-17,934,200-47,762,400-59,248,000-29,362,000-51,418,000
CFO
-42m
L+63.08%
0-14,434-22,756-6,878-3,565,800-3,463,200-2,126,000-2,768,900-4,808,500-7,262,100-9,058,300-14,527,500-15,757,000-12,073,500-45,256,500-49,715,100-25,813,000-42,097,000

Profile

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product candidature also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, and panic disorders. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with oral probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license agreement with Pherin Pharmaceuticals, Inc.; and license and collaboration agreement with EverInsight Therapeutics Inc. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
URL
https://www.vistagen.com/
IPO date
Oct 18, 2010
Employees
32
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
486
-54.32%
1,064
-568.72%
(227)
-120.47%
Cost of revenue
56,459
34,085
60,945
Unusual Expense (Income)
NOPBT
(55,973)
(33,021)
(61,172)
NOPBT Margin
26,948.02%
Operating Taxes
7
4
6
Tax Rate
NOPAT
(55,980)
(33,025)
(61,178)
Net income
(51,418)
75.12%
(29,362)
-50.44%
(59,248)
24.05%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,009
129,379
(6)
BB yield
-3.92%
-126.60%
0.02%
Debt
Debt current
561
1,100
591
Long-term debt
2,457
3,690
2,131,934
Deferred revenue
391
2,674
2,315
Other long-term liabilities
391
2,674
(2,127,193)
Net debt
(77,464)
(114,376)
2,115,888
Cash flow
Cash from operating activities
(42,097)
(25,813)
(49,715)
CAPEX
(191)
(61)
(212)
Cash from investing activities
(13,148)
(61)
(740)
Cash from financing activities
3,210
128,402
(1,042)
FCF
(55,536)
(32,512)
(60,869)
Balance
Cash
80,482
119,166
16,638
Long term investments
Excess cash
80,458
119,113
16,649
Stockholders' equity
(407,598)
(356,187)
(326,844)
Invested Capital
479,888
478,491
345,558
ROIC
ROCE
EV
Common stock shares outstanding
30,712
19,354
6,959
Price
2.50
-52.65%
5.28
41.14%
3.74
-89.94%
Market cap
76,780
-24.87%
102,192
292.55%
26,033
-89.40%
EV
(684)
(12,184)
2,141,921
EBITDA
(55,338)
(32,453)
(60,662)
EV/EBITDA
0.01
0.38
Interest
23
Interest/NOPBT